Skip to content

Effects of intragastric administration of L-tryptophan on appetite and gut hormone release in healthy, normal weight and obese subjects.

Effects of intragastric administration of L-tryptophan on appetite and energy intake, and gut hormone release, in healthy, normal weight and obese subjects.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12617001563358
Enrollment
25
Registered
2017-11-20
Start date
2017-11-30
Completion date
2019-10-16
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Obesity has reached epidemic proportions globally and is associated with serious co-morbidities, including type 2 diabetes. Once adipose tissue has been accumulated, and food intake is limited by low calorie diets, counter-regulatory mechanisms induce an increase in appetite and a decrease in energy expenditure, which makes weight loss very difficult to maintain. To combat the global burden of obesity and its co-morbidities, a major challenge lies in the development of effective therapies that increase fullness and satiety, and result in improvements in blood glucose control, while lacking adverse effects that are often associated with current therapies. There is increasing evidence that nutrient stimuli in the gastrointestinal tract play a central role in the control of energy intake and blood glucose. Proteins, and their building blocks, amino acids, are of interest, as high-protein diets are very effective for weight loss, particularly loss of fat, rather than muscle mass, and for improving postprandial glycaemic control, in obese individuals with and without type 2 diabetes. There is some evidence that a number of amino acids (including L-tryptophan) also have effects on energy intake, blood glucose and gut function in humans. We have previously investigated the effects of intraduodenal tryptophan and found that its effects to reduce subsequent energy intake were related to plasma cholecystokinin and tryptophan concentrations prior to the test meal. Thus, amino acids, here specifically tryptophan, may represent potential therapeutic approaches for obesity and type 2 diabetes. We have recently evaluated the effects of intragastric tryptophan at 3 g on gastric emptying, blood glucose, gut hormones, and appetite following a mixed-nutrient drink. Energy intake at a subsequent buffet style meal was also assessed. L-tryptophan slowed gastric emptying in both lean and obese groups. While overall energy intake was not affected, there was a decrease in energy intake in approximately half the subjects of each group, but less so in the obese. In the lean group, energy intake was found to be related to elevated concentrations of plasma tryptophan. A limitation of this study design may have been too long a duration between tryptophan administration and the meal at which energy intake was assessed (1 hr 15 min), thus mitigating the overall effect on energy intake. This new study has been designed with a shorter duration between tryptophan administration and buffet meal (30 min) and will investigate the effects of intragastric administration of L-tryptophan, vs saline control, on energy intake at a subsequent ad libitum buffet style meal, and the relationship with plasma gut hormone and tryptophan concentrations, appetite perceptions and intragastric volume in healthy, normal weight and obese, subjects.

Interventions

Subjects will receive, in randomized, double-blind fashion, an intragastric bolus infusion (200ml) of i) 3.0g L-tryptophan, ii) 1.5g L-tryptophan, or iii) saline (control), followed 30 min later by an ad libitum buffet style meal. Subjects will receive one infusion per study visit. Study visits will be separated by 3-7 days. For each study visit, subjects will be asked to attend the clinic at 8:30am (in a fasted state) at which time a baseline 2D ultrasound measurement of their stomach (to obt

Subjects will receive, in randomized, double-blind fashion, an intragastric bolus infusion (200ml) of i) 3.0g L-tryptophan, ii) 1.5g L-tryptophan, or iii) saline (control), followed 30 min later by an ad libitum buffet style meal. Subjects will receive one infusion per study visit. Study visits will be separated by 3-7 days. For each study visit, subjects will be asked to attend the clinic at 8:30am (in a fasted state) at which time a baseline 2D ultrasound measurement of their stomach (to obtain antral area for calculation of gastric emptying) will be taken. They will then be provided with a light breakfast (1 piece toast with spread of their choice, 1 cup of tea or water) to consume within 15 minutes . The breakfast provided will be the same at all visits. Water will be provided until 10 am after which time the subject will be asked to take nil by mouth until the lunch meal is provided. Immediately prior to t = -32 (~11:30am), a baseline blood sample, Visual analogue Scale (VAS) questionnaire, and a further ultrasound measurement will be collected. At t = -32 min the infusion will be administered over 2 min using a feeding tube. At t = -20, -10, and 0 min, further blood samples will be collected and VAS completed. At t = -30, -25, -20, -15, -10, -5 and t = 0, ultrasound measurements will be taken. At t = 0 min (~ midday), subjects will be presented with a cold, buffet-style meal. Subjects will be allowed 30 minutes to freely consume food from the buffet meal until comfortably full. At t = 30, 60, 90, 120, and 150 min, further blood samples will be taken and VAS administered.

Sponsors

Prof. Christine Feinle-Bisset
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

Healthy lean (BMI 19-25 kg/m2), and healthy obese (BMI 30-37 kg/m2), male subjects aged between 18 - 55 years, non-smoker, and without significant illness will be included in the study.

Exclusion criteria

Significant gastrointestinal symptoms, disease or surgery; Current gallbladder or pancreatic disease; Cardiovascular or respiratory diseases; Diagnosed type 2 diabetes; Any other illnesses as assessed by the investigator (including chronic illnesses not explicitly listed above); Use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, body weight or appetite (eg domperidone, cisapride, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.); Individuals with low ferritin (less than 30 ug/L) or iron (less than 8 umol/L) levels, or who have donated blood in the 12 weeks prior to taking part in the study; Lactose intolerance/other food allergy(ies); Vegetarians; Current intake of greater than 2 standard drinks on greater than 5 days per week; Current smokers of cigarettes/cigars/marijuana; Current intake of any illicit substance; High performance athletes; Inability to comprehend study protocol; Inability to tolerate naso-gastric tube; Healthy subjects only: Restrained eaters (score >12 on the three factor eating questionnaire). Obese subjects only: HbA1c <6.5%

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026